RCM
APGE icon

RA Capital Management’s Apogee Therapeutics APGE Stock Holding History

RA Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,569,491
Closed -$58.6M – 66
2025
Q1 		$58.6M Hold
1,569,491
– – 0.98% 22
2024
Q4 		$71.1M Sell
1,569,491
-392,372
-20% -$20M 0.95% 25
2024
Q3 		$115M Hold
1,961,863
– – 1.33% 22
2024
Q2 		$77.2M Sell
1,961,863
-16,038
-0.8% -$778K 1.02% 27
2024
Q1 		$131M Hold
1,977,901
– – 1.67% 18
2023
Q4 		$55.3M Hold
1,977,901
– – 0.86% 29
2023
Q3 		$42.1M Buy
+1,977,901
New +$43.6M 0.83% 34

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

RA Capital Management's APGE Position: Q2 2025 in Review

RA Capital Management sold out of Apogee Therapeutics (APGE) in Q2 2025, closing a stake of 1,569,491 shares — an estimated $58.6M sold.

RA Capital Management first reported a position in APGE in Q3 2023 and held it in 7 quarters. The position peaked at $131M in Q1 2024. 182 funds tracked by Wall St. Rank hold APGE as of Q2 2025.

  • RA Capital Management reported no remaining Apogee Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RA Capital Management sold 1,569,491 Apogee Therapeutics shares in Q2 2025, an estimated $58.6M.
  • RA Capital Management first reported a position in Apogee Therapeutics in Q3 2023 and held it in 7 quarters.
  • RA Capital Management's Apogee Therapeutics position peaked at $131M in Q1 2024.
  • 182 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2025.

Based on RA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.